Accepted for Publication: July 17, 2012.
Published Online: January 14, 2013. doi:10.1001/2013.jamaneurol.337
Author Contributions:Study concept and design: Fields, Labovitz, and French. Acquisition of data: Fields and Labovitz. Analysis and interpretation of data: Labovitz and French. Drafting of the manuscript: Fields and Labovitz. Critical revision of the manuscript for important intellectual content: Fields, Labovitz, and French. Statistical analysis: Labovitz. Obtained funding: Fields and French. Administrative, technical, and material support: Labovitz. Study supervision: Labovitz and French.
Conflict of Interest Disclosures: The authors conducted research for the NYU Comprehensive Epilepsy Center, which was under a paid consultant agreement with Pfizer to conduct this study and write this article. Dr French reported having received grant funding from The Milken Foundation, the Epilepsy Therapy Project, and National Institute of Neurological Disorders and Stroke, and reported serving as president of the Epilepsy Study Consortium, a nonprofit organization; NYU receives a fixed amount from the Epilepsy Study Consortium toward her salary for work performed on behalf of the Epilepsy Study Consortium, for consulting, and for clinical trial–related activities.
Funding/Support: This study was funded by Pfizer. Drs Fields and French were employees of NYU Comprehensive Epilepsy Center at the time this study was conducted.
Online-Only Material: Listen to an author interview about this article, and others, at http://bit.ly/MT7xg4.
Additional Contributions: We thank undergraduate students Shani Zitter, Rebecca Radwani, and Agnieszka Bulanda for their contribution to the data collection for this study.